Research suggests that Bacillus coagulans may help reduce common IBS symptoms, including abdominal pain, bloating, and stool irregularities, based on evidence from four randomized, double-blind, placebo-controlled trials conducted across different populations and strain variants. Studies indicate consistent directional support across these trials, with participants taking various B. coagulans strains generally reporting greater symptom improvements than those receiving placebo, and all studies noted the probiotic was well tolerated with no serious adverse events. One trial also reported improvements in psychological markers such as stress, though it found no significant change in the inflammatory marker interleukin-6, suggesting the mechanisms at work may not be fully understood. Limitations worth noting include relatively small sample sizes across all four studies, short intervention periods ranging from eight to twelve weeks, and the use of different strains and formulations, which makes it difficult to draw broad conclusions or apply findings universally.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritabl... | RCT | 2024 | Supports | 100 |
| Bacillus coagulans significantly improved abdominal pain and bloating in pati... | RCT | 2009 | Supports | 95 |
| The role of Weizmannia (Bacillus) coagulans LMG S-31876 in treating IBS-diarr... | Other | 2023 | Supports | 90 |
| Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syn... | RCT | 2018 | Supports | 85 |